Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanofi filings document a foreign biopharmaceutical issuer whose American depositary shares represent interests in ordinary shares. Its SEC record includes Form 6-K reports and Form 20-F annual reporting that incorporate parent-company press releases, financial reports, governance materials and ADR-related disclosure.
Sanofi’s filings cover operating results, research and development spending, product and pipeline updates, regulatory approvals and designations, and therapeutic areas such as immunology, vaccines, rare diseases, oncology, respiratory disease and diabetes. They also document bond issuance under its Euro Medium Term Note programme, share buyback activity, annual meeting resolutions, board and executive appointments, risk factors and capital-structure matters.
Sanofi (SNY) filed a preliminary 424(b)(5) prospectus supplement to issue multiple tranches of unsecured, unsubordinated notes, including floating‑rate series tied to Compounded SOFR and fixed‑rate series. The notes rank equally with Sanofi’s other unsecured debt, are not subject to a sinking fund, and will not be listed on an exchange.
The floating‑rate notes reset quarterly at Compounded SOFR plus a margin and pay interest quarterly; the fixed‑rate notes pay interest semi‑annually. Interest begins accruing in 2025 with first payments in 2026. Optional redemption for fixed‑rate tranches includes a make‑whole call and a par call window, and all notes include tax redemption provisions. Minimum denominations are $2,000 and integral multiples of $1,000, delivered in book‑entry form through DTC, Euroclear and Clearstream. Sanofi intends to use net proceeds for general corporate purposes.
Sanofi furnished a Form 6‑K providing H1 2025 condensed consolidated results and updates. The company lost control of Opella on April 30, 2025; from May 1, 2025 OPAL JV Co is accounted for using the equity method. H1 operating cash flows reflect routine items, including income tax paid of €1,355 million, interest paid of €206 million, and interest received of €170 million.
Financing and liabilities were active across the period. As of June 30, 2025, current other bank borrowings included €4,535 million related to the US commercial paper program and €230 million related to the French program, while a financing cash‑flow line mainly comprised the US commercial paper program of €3,353 million (vs €6,060 million in H1 2024). Net debt metrics exclude lease liabilities of €1,776 million. The liability for royalties payable to Sobi on US Beyfortus net sales was €1,756 million, with nominal payments estimated at €1,027 million within one to five years and €2,293 million thereafter. The period included impairment losses of €210 million linked to R&D projects, a €17 million tax expense from Pillar Two, and an €88 million tax expense tied to the gain on the Opella deconsolidation.
Sanofi furnished a Form 6-K for October 2025, providing an update via an attached press release. Exhibit 99.1 is titled “Q3: continued sales and earnings progress” and is dated October 24, 2025. This filing shares the company’s quarterly narrative through that press release.
The report was signed on October 24, 2025 by Alexandra Roger, Head of Legal Corporate & Finance. Readers can reference Exhibit 99.1 for Sanofi’s Q3 themes around sales and earnings performance.
Sanofi furnished a Form 6-K listing recent company press releases from October 17–20, 2025. The exhibits cover: an EU regulatory review update for Rezurock in chronic graft-vs-host disease; a CHMP recommendation for EU approval of Wayrilz to treat immune thrombocytopenia; new data showing Sanofi’s high-dose influenza vaccine provided superior protection for older adults against hospitalization versus standard-dose; ESMO phase 2 findings for AlphaMedix supporting first-in-class potential in gastroenteropancreatic neuroendocrine tumors; and Tzield being accepted for expedited review in the US through the FDA Commissioner’s National Priority Voucher pilot program.
The filing compiles these updates for investors and incorporates the press releases by reference.
Sanofi furnished a Form 6-K announcing a press release dated October 8, 2025. The release states that AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in a phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This update highlights mid-stage clinical results disclosed via an attached exhibit.
Sanofi reported two corporate developments in an exhibit list attached to its Form 6-K. A press release dated September 23, 2025, states that Sanofi's investigational medicine SAR446268 received U.S. Fast Track designation for the treatment of non-congenital myotonic dystrophy type 1, signaling accelerated regulatory review for that indication. A separate press release dated September 24, 2025, states Sanofi is committing an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation.
Both items are presented as exhibits to the current report and indicate near-term regulatory and strategic investment activity explicitly disclosed by the company.
Sanofi filed a report summarizing two regulatory milestones from September 2025. The company notes a press release on a positive CHMP opinion in the European Union for Dupixent, developed with Regeneron, for treating chronic spontaneous urticaria. A second press release covers an update on the U.S. regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis. The report itself mainly serves to formally furnish these press releases to investors.
Sanofi filed a Form 6-K to share a press release about its experimental medicine amlitelimab. The release states that amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis. This means the treatment achieved the main goals and important additional measures set for this late-stage clinical trial, suggesting a broadly positive result for this patient group.
Sanofi (SNY) filed a Form 6-K that includes an exhibit: a press release dated August 29, 2025 announcing that Wayrilz was approved in the United States as the first BTK inhibitor indicated for immune thrombocytopenia. The filing itself is dated September 3, 2025 and is signed by Alexandra Roger, Head of Legal Corporate & Finance.
The disclosure is concise: it notifies investors that a regulatory approval milestone was achieved for a new therapeutic option in immune thrombocytopenia and that the company has publicly released that information via a press release attached as Exhibit 99.1.
Sanofi filed a Form 6-K reporting an attached press release dated August 14, 2025, announcing that its investigational drug rilzabrutinib received orphan designation in the European Union for the treatment of IgG4-related disease. The filing includes the company signature block signed by Alexandra Roger, Head of Legal Corporate & Finance, dated August 29, 2025. The document is a brief disclosure of the press release and does not contain financial results, transaction details, or additional corporate commentary.